Several liposomal drugs have received clinical approval for the treatment of cancer due to the reduced side effects and/or improved therapeutic efficacy in comparison to their respective free drug counterparts. In this study, nanoliposomes are designed as multidrug carriers for codelivering gemcitabine hydrochloride (Gemzar) and paclitaxel (Taxol) and evaluating their anticancer activity in several triple negative human breast cancer cell lines and in a mouse model of metastatic breast cancer. The results demonstrate that the nanoliposomes significantly decrease the cell viability of breast cancer cells compared to combination treatment with the free drugs. Furthermore, the chemotherapeutics coloaded nanoliposomes dramatically decrease the tumor growth and improve survival times, while combination treatment with Gemzar and Taxol has a modest effect on cancer progression. Moreover, pharmacokinetic analysis demonstrates that nanoliposomes increase the half-life of gemcitabine hydrochloride and paclitaxel 6.3-fold and 1.7-fold, respectively. Taken together, the findings indicate that gemcitabine hydrochloride and paclitaxel-coloaded nanoliposomes can provide an effective treatment strategy for metastatic breast cancer.

Nanoliposomes as Multidrug Carrier of Gemcitabine/Paclitaxel for the Effective Treatment of Metastatic Breast Cancer Disease: A Comparison with Gemzar and Taxol

Celia C.;Cristiano M. C.;Froiio F.;Di Francesco M.;d'Avanzo N.;Fresta M.
2021-01-01

Abstract

Several liposomal drugs have received clinical approval for the treatment of cancer due to the reduced side effects and/or improved therapeutic efficacy in comparison to their respective free drug counterparts. In this study, nanoliposomes are designed as multidrug carriers for codelivering gemcitabine hydrochloride (Gemzar) and paclitaxel (Taxol) and evaluating their anticancer activity in several triple negative human breast cancer cell lines and in a mouse model of metastatic breast cancer. The results demonstrate that the nanoliposomes significantly decrease the cell viability of breast cancer cells compared to combination treatment with the free drugs. Furthermore, the chemotherapeutics coloaded nanoliposomes dramatically decrease the tumor growth and improve survival times, while combination treatment with Gemzar and Taxol has a modest effect on cancer progression. Moreover, pharmacokinetic analysis demonstrates that nanoliposomes increase the half-life of gemcitabine hydrochloride and paclitaxel 6.3-fold and 1.7-fold, respectively. Taken together, the findings indicate that gemcitabine hydrochloride and paclitaxel-coloaded nanoliposomes can provide an effective treatment strategy for metastatic breast cancer.
2021
breast cancer
gemcitabine hydrochloride
nanoliposomes
nanomedicine
paclitaxel
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.12317/89321
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 19
social impact